NucleoCounter® NC-202™
Therapeutic Antibody Production / GMP Workflows
CommercialMarketed
Key Facts
Indication
Therapeutic Antibody Production / GMP Workflows
Phase
Commercial
Status
Marketed
Company
About ChemoMetec
Founded in 1997 and headquartered in Denmark, ChemoMetec designs and manufactures automated cell counters and cell analysers used globally in biotech, pharma, and academic research. Its core technology provides rapid, reproducible, and reliable cell counting, with instruments like the NucleoCounter® NC-202™ and XcytoMatic® 40 being 21 CFR Part 11/GMP-ready for integration into regulated workflows. The company is publicly listed on the Nasdaq Copenhagen exchange and is strategically positioned to capitalize on the growth of advanced therapies and bioprocessing.
View full company profile